The effect of vaginal Erbium-YAG laser treatment for the genitourinary syndrome of menopause: a randomized controlled study

Background: Genitourinary Syndrome of Menopause (GSM) is one of the important global health concerns due to its impact on quality of life. The intra-vaginal laser therapy has been used for treatment of GSM. The erbium in yttrium aluminum-garnet crystal or Er:YAG vaginal laser (VEL) induce the regenerative process of the vaginal mucosa.
Source: Maturitas - Category: Primary Care Authors: Tags: P11 Source Type: research

Related Links:

Genitourinary syndrome of menopause (GSM) include genital symptoms of dryness, burning, irritation, but also sexual symptoms of lack of lubrication, discomfort or pain, and impaired function, as well as urinary symptoms of urgency, dysuria and recurrent urinary tract infections. Reported prevalence rates of vaginal dryness due to vulvovaginal atrophy (VVA) or GSM vary, but it is estimated that approximately 15% of premenopausal and up to 57% of postmenopausal women experience this condition. Local vaginal estrogen administration is the treatment of choice for VVA atrophy, although lacking long time efficacy and safety.
Source: Maturitas - Category: Primary Care Authors: Tags: INV63 Source Type: research
Is laser therapy safe and effective for treating genitourinary syndrome of menopause? This paper presents four cases with complications due to unapproved use of lasers for vaginal symptoms.Menopause
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news
Conclusions: Laser therapy for the vagina shows excellent promise for the treatment of GSM in some women; however, complications such as fibrosis, scarring, agglutination, and penetration injury have been documented. Food and Drug Administration–approved products for GSM should be considered frontline treatments until long-term, prospective, randomized, sham-controlled trials are conducted that confirm efficacy and safety for device treatments.
Source: Menopause - Category: OBGYN Tags: Case Report Source Type: research
Authors: Donders GGG, Ruban K, Bellen G, Grinceviciene S Abstract INTRODUCTION: Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low dose estrogen product is the main therapy. Ultra-low-dose vaginal estriol is safe and sufficient in most cases, even in breast cancer patients, while hyaluronic acid can help women who cannot or do not want to use hormones. Areas covered: The authors provide an overview ...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Objective: The aim of this study is to assess the efficacy of microablative fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) management, when three, four, or five laser therapies were applied in a follow-up period of 12 months. Methods: Retrospective study evaluating GSM symptoms at baseline, and 1, 3, 6, and 12 months after last laser therapy. Visual analog scale, International Consultation on Incontinence Questionnaires- Female Urinary Tract Symptoms, International Consultation on Incontinence Questionnaires-Urinary Incontinence Short Form, Urogenital Distress Inventory-6, and Female Sexual...
Source: Menopause - Category: OBGYN Tags: Original Articles Source Type: research
Introduction: A growing body of evidences shows stimulating results on the use of Vaginal Erbium Laser (VEL) for the treatment of genitourinary syndrome of menopause (GSM) and stress urinary incontinence (SUI). However, no data on the duration of laser effects after 6 –12 months are currently available.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Session 02 – Menopause Source Type: research
CONCLUSIONS: Vaginal laser therapy has shown potential and demonstrated its safety for use in urology as either a complementary or alternative treatment to existing treatment options, such as topical hormonal therapies, pelvic floor exercises or surgical procedures. It is necessary to define it as separate from aesthetic procedures. PMID: 30721329 [PubMed - as supplied by publisher]
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research
AbstractThis committee opinion reviews the laser-based vaginal devices for treatment of genitourinary syndrome of menopause, vaginal laxity, and stress urinary incontinence. The United States Food and Drug Administration has issued a warning for unsubstantiated advertising and use of energy-based devices. Well-designed case –control studies are required to further investigate the potential benefits, harm, and efficacy of laser therapy in the treatment of genitourinary syndrome of menopause, vaginal laxity, and stress urinary incontinence. The therapeutic advantages of nonsurgical laser-based devices in urogynecology ...
Source: International Urogynecology Journal - Category: OBGYN Source Type: research
Conditions:   Genitourinary Syndrome of Menopause;   Vaginal Atrophy;   Breast Cancer;   Dyspareunia Intervention:   Device: Microablative Fractional CO2 Laser Therapy Sponsor:   National and Kapodistrian University of Athens Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Laser Therapy | Men | Menopause | Primary Care | Study